Corporate Support
Sitemap
Singapore

ShareInvestor.com

Mobile Edition
Mode - Streaming
Switch to Static Mode?

Price Highlight

Index Highlight

Chart
STI
3,175.9
1.7 (0.05%)

 

  • STI Straits Times Index
    3,175.9
    1.7 (0.05%)
     
  • KLCI FTSE Bursa Malaysia KLCI
    1,567.2
    3.6 (0.23%)
    Index delayed 15 minutes
  • HSI Hang Seng Index
    26,379.0
    161.9 (0.62%)
    Index delayed 15 minutes
  • SSE SSE Composite Index
    2,898.4
    -1.1 (-0.04%)
    Index delayed 15 minutes
  • N225 Nikkei 225
    23,355.4
    55.3 (0.24%)
    Index delayed 20 minutes
  • JCI Jakarta Composite Index
    6,162.9
    10.8 (0.18%)
    Index delayed 10 minutes
  • KOR KOSPI
    2,077.2
    16.5 (0.80%)
    Index delayed 20 minutes
  • XAO XAO
    6,813.5
    22.4 (0.33%)
     

SGX Market

Bursa Market

HKEx Market

SET Market

IDX Market

ASX Market

NYSE Market

NASDAQ Market

NYSE American Market

  • Volume: 355.5M
  • Value: 464.9M
  • Rise: 98
  • Fall: 118
  • Unch: 610

Intraday Market Ticker Help

Intraday Market Ticker
Time Name Type Price Vol
  • Top Active

  • Top Gainer

  • Top Loser

Top Counters
Name Last Change
Golden Agri-Res0.225-0.005
Rex Intl0.169-0.005
YZJ Shipbldg SGD1.090-0.010
Tritech0.026-
Mapletree Log Tr1.730+0.010
SingTel3.410-
AusGroup^0.030-
Genting Sing0.915-
Chasen^0.073+0.006
ManulifeReit USD1.000+0.020

World Indices

World Indices
Name Last Change
Nasdaq 8,570.7 +4.0
HSI 26,413.3 +196.2
HSCEI 10,382.1 +60.3
Jakarta 6,162.9 +10.8
Nikkei 225 23,354.4 +54.3
SSE Comp 2,901.1 +1.6
Shanghai A 3,039.9 +1.7
Shanghai B 242.5 +0.9
PSE Comp 0.0
KOSPI 2,079.4 +18.7

Asian Indices delayed. US Indices updated twice daily at 7:30am and 7:30pm.

Fundamental - Factsheet

Help
  • Factsheet

  • Print

MOTIF BIO PLC ADR EACH REPR 20 SHS SPON MOTIF BIO PLC ADR EACH REPR 20 SHS SPON
Updated on 05 Dec 2019 (End of trading day)
Last (USD): 0.120 Change: -0.010 High: 0.129 Remarks: -
Change (%): -7.69 Low: 0.110
Open 0.125 Yesterday's Close 0.13
Buy Price - Sell Price -
Buy Volume (share) - Sell Volume (share) -
Cumulative Volume (share) 664,207 Cumulative Value
Click to show Stock Prices chart

Key Statistics

EPS (USD) a -0.81529 Trailing EPS (USD) e -0.72189 NAV (USD) b -0.6495
PE a - Trailing PE f - Price / NAV b -0.1848
Dividend (USD) d - Cash In Hand (USD) g 0.1073 Issued & Paid-up Shares c 17,124,500
Dividend Yield (%) d - Price / Cash In Hand g 1.118 Treasury Shares h -
Beta - 75 Daysi -2.723 R-Squared - 75 Days(%)i 3.11 Market Cap (M) 2.055
Beta - 500 Daysi 0.043 R-Squared - 500 Days (%)i - Enterprise Value (M) 6.956
Piotroski F Score 1 Exchange Code MTFB Par Value ( $ ) n.a.
52 Weeks Volatility (%) 196.81 Free Float (%) -
Sector & Industry Health Technology - Biotechnology
Notes:
  1. Based on latest Full Year results announcement, adjusted for the current number of shares.
  2. Based on latest results announcement (Full Year, Half Year or Interim), adjusted for carrying value of "Other Share Capital", illustrative financial effects of corporate actions (if applicable) and the current number of shares.
  3. Rounded to the nearest thousand. Updated on 02 May 2019.Please click here for more information.
  4. Dividend is based on latest Full Year results announcement, adjusted for current number of shares and excludes special dividend.
  5. Summation of the earnings from the latest 4 Quarter (or 2 Half Year) results announcement, adjusted for the current number of shares.
  6. Based on Trailing EPS.
  7. Based on reported cash and cash equivalents at end and extracted from the latest results announcement (Full Year, Half Year or Interim), adjusted for the current number of shares.
  8. Rounded to the nearest thousand. Updated on 04 Aug 2016.
  9. Beta and R-Squared are calculated in relation to the market index using the historical daily closing values of the stock and index as data points.

Peer Comparison

Type Name Market Market Cap (M)a PE b Trailing PE c Price / NAV d Dividend Yield (%)d
Reference MOTIF BIO PLC ADR EACH REPR 20 SHS SPON NASDAQ 2.055 - - -0.1848 -
Industry Biotechnology NASDAQ 2,315.531 398.751 168.111 5.7928 0.755
Local Peer AMGEN INC NASDAQ 138,688.487 16.522 17.192 12.6923 2.397
Local Peer GILEAD SCIENCES INC NASDAQ 83,411.340 15.291 30.973 4.0483 3.504
Local Peer VERTEX PHARMACEUTICAL NASDAQ 57,362.450 27.362 26.758 10.9191 -
Local Peer BIOGEN INC NASDAQ 54,022.530 12.193 10.012 3.8599 -
Local Peer ILLUMINA INC NASDAQ 47,012.070 56.915 48.317 10.5907 -
Local Peer REGENERON PHARMACEUTICALS INC NASDAQ 40,442.248 16.545 18.861 3.8500 -
Local Peer ALEXION PHARMACEUTICAL INC NASDAQ 23,771.079 306.328 16.168 2.2929 -
Local Peer INCYTE CORPORATION NASDAQ 20,245.164 184.900 49.993 8.3570 -
Local Peer SEATTLE GENETICS INC NASDAQ 20,079.584 - - 11.2832 -
Local Peer BIOMARIN PHARMACEUTICAL NASDAQ 14,384.370 - - 4.6787 -
Local Peer ALNYLAM PHARMACEUTICALS INC NASDAQ 13,850.403 - - 8.6183 -
Local Peer GALAPAGOS NV SPON ADR REPR 1 ORD SHS NASDAQ 13,552.263 - 43.666 4.9032 -
Other Local Peers EXACT SCIENCES CORP (NASDAQ), BEIGENE LTD SPON ADS EACH REPR 13 ORD SHS (NASDAQ), NEUROCRINE BIOSCIENCES INC (NASDAQ), IONIS PHARMACEUTICALS INC (NASDAQ), BIO-TECHNE CORP (NASDAQ), SAREPTA THERAPEUTICS INC (NASDAQ), MODERNA INC (NASDAQ), ACADIA PHARMACEUTICALS INC (NASDAQ), ARROWHEAD PHARMACEUTICALS INC (NASDAQ), 10X GENOMICS INC (NASDAQ), ASCENDIS PHARMA A/S SPON ADR EACH REP 1 ORD SHS (NASDAQ), EXELIXIS INC (NASDAQ), BIONTECH SE SPON ADS EACH REP 1 ORD SHS (NASDAQ), REPLIGEN CORP (NASDAQ), CHINA BIOLOGIC PRODUCTS HLDGS INC (NASDAQ), BLUEBIRD BIO INC (NASDAQ), GLOBAL BLOOD THERAPEUTICS INC (NASDAQ), CRISPR THERAPEUTICS AG (NASDAQ), MIRATI THERAPEUTICS INC (NASDAQ), SPARK THERAPEUTICS INC (NASDAQ), MORPHOSYS SPON ADS EACH REP 0.25 ORD SHS (NASDAQ), FIBROGEN INC (NASDAQ), BLUEPRINT MEDICINES CORP (NASDAQ), ALLOGENE THERAPEUTICS INC (NASDAQ), NEKTAR THERAPEUTICS (NASDAQ), IMMUNOMEDICS INC (NASDAQ), ALKERMES PLC (NASDAQ), IOVANCE BIOTHERAPEUTICS INC (NASDAQ), PTC THERAPEUTICS INC (NASDAQ), HALOZYME THERAPEUTICS INC (NASDAQ), UNIQURE N.V. (NASDAQ), AMICUS THERAPEUTICS INC (NASDAQ), KODIAK SCIENCES INC (NASDAQ), AUDENTES THERAPEUTICS INC (NASDAQ), ZAI LAB LIMITED ADS EACH REP 1 ORD SHS (NASDAQ), AGIOS PHARMACEUTICALS INC (NASDAQ), NATERA INC (NASDAQ), DECIPHERA PHARMACEUTICALS INC (NASDAQ), ACCELERON PHARMA (NASDAQ), ULTRAGENYX PHARMACEUTICAL INC (NASDAQ), HERON THERAPEUTICS INC (NASDAQ), ARENA PHARMACEUTICALS INC (NASDAQ), XENCOR INC (NASDAQ), EIDOS THERAPEUTICS INC (NASDAQ), INSMED INC (NASDAQ), MYRIAD GENETICS INC (NASDAQ), LIGAND PHARMACEUTICAL INC (NASDAQ), AIMMUNE THERAPEUTICS INC (NASDAQ), DICERNA PHARMACEUTICALS INC. (NASDAQ), DENALI THERAPEUTICS INC (NASDAQ), REGENXBIO INC (NASDAQ), MOMENTA PHARMACEUTICALS INC (NASDAQ), CHEMOCENTRYX INC (NASDAQ), EDITAS MEDICINE INC (NASDAQ), ARVINAS INC (NASDAQ), VIR BIOTECHNOLOGY INC (NASDAQ), EPIZYME INC (NASDAQ), ESPERION THERAPEUTICS INC (NASDAQ), VERACYTE INC (NASDAQ), NEXTCURE INC (NASDAQ), SANGAMO THERAPEUTICS INC (NASDAQ), ALECTOR INC (NASDAQ), VIELA BIO INC (NASDAQ), COHERUS BIOSCIENCES INC (NASDAQ), ENANTA PHARMACEUTICALS INC (NASDAQ), WAVE LIFE SCIENCES LTD (NASDAQ), ZEALAND PHARMA AS SPON ADR EACH REP 1 ORD SHS (NASDAQ), KARYOPHARM THERAPEUTICS INC (NASDAQ), NGM BIOPHARMACEUTICALS INC (NASDAQ), OPKO HEALTH INC (NASDAQ), FATE THERAPEUTICS (NASDAQ), RADIUS HEALTH INC (NASDAQ), RHYTHM PHARMACEUTICALS INC (NASDAQ), SPECTRUM PHARMACEUTICALS INC (NASDAQ), ROCKET PHARMACEUTICALS INC (NASDAQ), ZIOPHARM ONCOLOGY INC (NASDAQ), NANOSTRING TECHNOLOGIES INC (NASDAQ), LUMINEX CORP(DEL) (NASDAQ), VANDA PHARMACE INC (NASDAQ), AVITA MEDICAL LTD SPON ADS EACH REP 20 ORD SHS (NASDAQ), INTREXON CORP (NASDAQ), ACHILLION PHARMACEUTICALS INC (NASDAQ), INTELLIA THERAPEUTICS INC (NASDAQ), CORTEXYME INC (NASDAQ), PRECISION BIOSCIENCES INC (NASDAQ), STOKE THERAPEUTICS INC (NASDAQ), TG THERAPEUTICS INC (NASDAQ), CARA THERAPEUTICS INC (NASDAQ), AURINIA PHARMACEUTICALS INC (NASDAQ), HOMOLOGY MEDICINES INC (NASDAQ), PACIFIC BIOSCIENCES CALIFORNIA INC (NASDAQ), TWIST BIOSCIENCE CORPORATION (NASDAQ), ATARA BIOTHERAPEUTICS INC (NASDAQ), OMEROS CORP (NASDAQ), DBV TECHNOLOGIES SPON ADR EACH REPR 0.5 ORD (NASDAQ), RUBIUS THERAPEUTICS INC (NASDAQ), ADVERUM BIOTECHNOLOGIES INC (NASDAQ), MEIRAGTX HOLDINGS PLC (NASDAQ), AUTOLUS THERAPEUTICS PLC SPON ADS EA REP 1 ORD SHS (NASDAQ), AKEBIA THERAPEUTICS INC (NASDAQ), FLEXION THERAPEUTICS INC (NASDAQ), KURA ONCOLOGY INC (NASDAQ), SYNTHORX INC (NASDAQ), MESOBLAST LTD SPON ADR EACH REP 5 SHS (NASDAQ), CLOVIS ONCOLOGY INC (NASDAQ), UROGEN PHARMA LTD (NASDAQ), CELLECTIS ADS EACH REPR 1 ORD SPON (NASDAQ), GENFIT SPON ADS EACH REP 1 ORD SHS (NASDAQ), SORRENTO THERAPEUTICS INC (NASDAQ), IMMUNOGEN INC (NASDAQ), TRANSLATE BIO INC (NASDAQ), RAPT THERAPEUTICS INC (NASDAQ), CYTOKINETICS INC (NASDAQ), RETROPHIN INC (NASDAQ), MOLECULAR TEMPLATES INC (NASDAQ), INTRA-CELLUAR THERAPIES INC (NASDAQ), AVROBIO INC (NASDAQ), AGENUS INC (NASDAQ), VOYAGER THERAPEUTICS INC (NASDAQ), VIKING THERAPEUTICS INC (NASDAQ), MAGENTA THERAPEUTICS INC (NASDAQ), PROTHENA CORP PLC (NASDAQ), PREVAIL THERAPEUTICS INC (NASDAQ), STEMLINE THERAPEUTICS INC (NASDAQ), REPLIMUNE GROUP INC (NASDAQ), INNATE PHARMA SPON ADS EACH REP 1 ORD SHS (NASDAQ), FREQUENCY THERAPEUTICS INC (NASDAQ), MERUS B V (NASDAQ), DYNAVAX TECHNOLOGIES CORP (NASDAQ), MACROGENICS INC (NASDAQ), XBIOTECH INC (NASDAQ), SINOVAC BIOTECH LTD (NASDAQ), HARPOON THERAPEUTICS INC (NASDAQ), MORPHIC HOLDING INC (NASDAQ), DERMIRA INC (NASDAQ), BIOCRYST PHARMACEUTICALS INC (NASDAQ), PROGENICS PHARMACEUTICALS INC (NASDAQ), ARDELYX INC (NASDAQ), STEALTH BIOTHERAPEUTICS CORP SPON ADS EACH REP 12 ORD SHS (NASDAQ), APPLIED THERAPEUTICS INC (NASDAQ), LEXICON PHARMACEUTICALS INC (NASDAQ), ANAPTYSBIO INC (NASDAQ), PROQR THERAPEUTICS N V (NASDAQ), MERIDIAN BIOSCIENCE INC COM (NASDAQ), BELLUS HEALTH INC (NASDAQ), RECRO PHARMA INC (NASDAQ), XENON PHARMACEUTICALS INC (NASDAQ), RIGEL PHARMACEUTICALS INC (NASDAQ), PUMA BIOTECHNOLOGY INC (NASDAQ), CELLULAR BIOMEDICINE GROUP INC (NASDAQ), MEDICINOVA INC (NASDAQ), COMPUGEN (NASDAQ), PDL BIOPHARMA INC (NASDAQ), CORBUS PHARMACEUTICALS HOLDINGS IN (NASDAQ), AVID BIOSERVICES INC (NASDAQ), EIGER BIOPHARMACEUTICALS INC (NASDAQ), UNITY BIOTECHNOLOGY INC (NASDAQ), EVOFEM BIOSCIENCES INC (NASDAQ), CASI PHARMACEUTICALS INC (NASDAQ), GERON CORP (NASDAQ), CYTOMX THERAPEUTICS INC (NASDAQ), KAMADA (NASDAQ), CUE BIOPHARMA INC (NASDAQ), PERSONALIS INC (NASDAQ), GLYCOMIMETICS INC (NASDAQ), JOUNCE THERAPEUTICS INC (NASDAQ), SERES THERAPEUTICS (NASDAQ), MANNKIND CORPORATION (NASDAQ), NEPTUNE WELLNESS SOLUTIONS INC (NASDAQ), CALITHERA BIOSCIENCES INC (NASDAQ), ADMA BIOLOGICS INC (NASDAQ), SCHOLAR ROCK HOLDING CORPORATION (NASDAQ), MINERVA NEUROSCIENCES INC (NASDAQ), CABALETTA BIO INC (NASDAQ), BIOFRONTERA AG SPON ADS EACH REP TWO ORD SHS (NASDAQ), CHIASMA INC (NASDAQ), REDHILL BIOPHARMA LTD SPON ADS EA REPR 10 ORD ILS0.00 (NASDAQ), ELOXX PHARMACEUTICALS INC (NASDAQ), NUCANA PLC SPON ADR EACH REP 1 ORD SHS (NASDAQ), PIERIS PHARMACEUTICALS INC (NASDAQ), PROTAGONIST THERAPEUTICS INC (NASDAQ), XOMA CORP (NASDAQ), SOLID BIOSCIENCES INC (NASDAQ), ATHERSYS INC (NASDAQ), SYROS PHARMACEUTICALS INC (NASDAQ), MERSANA THERAPEUTICS INC (NASDAQ), SYNDAX PHARMACEUTICALS INC (NASDAQ), CONCERT PHARMACEUTICALS INC (NASDAQ), ARAVIVE INC (NASDAQ), TAIWAN LIPOSOME COMPANY LTD SPON ADS EACH REP 2 ORD SHS (NASDAQ), AFFIMED N V (NASDAQ), GALECTIN THERAPEUTICS INC (NASDAQ), IVERIC BIO INC (NASDAQ), X4 PHARMACEUTICALS INC (NASDAQ), DYADIC INTERNATIONAL INC (NASDAQ), ANAVEX LIFE SCIENCES CORPORATION (NASDAQ), CHIMERIX INC (NASDAQ), NABRIVA THERAPEUTICS PLC (NASDAQ), EDAP TMS S.A. SPON ADR EACH REPR 1 ORD SHARE (NASDAQ), NANTKWEST INC (NASDAQ), VBI VACCINES INC CDA (NASDAQ), APTOSE BIOSCIENCES INC (NASDAQ), FORTRESS BIOTECH INC (NASDAQ), FIVE PRIME THERAPEUTICS (NASDAQ), PROTEOSTASIS THERAPEUTICS INC (NASDAQ), IMV INC (NASDAQ), LIMINAL BIOSCIENCES INC (NASDAQ), BICYCLE THERAPEUTICS PLC SPON ADS EACH REP 1 ORD SHS (NASDAQ), ALDEYRA THERAPEUTICS (NASDAQ), NOVAVAX INC (NASDAQ), ARBUTUS BIOPHARMA CORP (NASDAQ), ADAPTIMMUNE THERAPEUTICS PLC ADS EACH REPR 6 SHS (SPONS) (NASDAQ), SESEN BIO INC (NASDAQ), AVEO PHARMACEUTICALS INC (NASDAQ), FENNEC PHARMACEUTICALS INC (NASDAQ), AXOVANT GENE THERAPIES LTD (NASDAQ), AVALON GLOBOCARE CORP (NASDAQ), HARVARD BIOSCIENCE INC (NASDAQ), CYMABAY THERAPEUTICS INC (NASDAQ), BIOXCEL THERAPEUTICS INC (NASDAQ), AXCELLA HEALTH INC (NASDAQ), CORREVIO PHARMA CORP (NASDAQ), VERASTEM INC (NASDAQ), PARATEK PHARMACEUTICALS INC (NASDAQ), STRONGBRIDGE BIOPHARMA PLC (NASDAQ), ADURO BIOTECH INC (NASDAQ), VTV THERAPEUTICS INC (NASDAQ), LA JOLLA PHARMACEUTICAL CO (NASDAQ), BRAINSTROM CELL THERAPEUTICS (NASDAQ), INFLARX N V (NASDAQ), ASLAN PHARMACEUTICALS LIMITED ADS EACH REP 5 ORD SHS (NASDAQ), ACORDA THERAPEUTICS INC (NASDAQ), CIDARA THERAPEUTICS INC (NASDAQ), CHAMPIONS ONCOLOGY INC (NASDAQ), OTONOMY INC (NASDAQ), ERYTECH PHARMA SPON ADR EACH REPR 1 ORD (NASDAQ), ANIXA BIOSCIENCES INC (NASDAQ), TIZIANA LIFE SCIENCES PLC SPON ADS EACH REPR 10 ORD SHS (NASDAQ), SELECTA BIOSCIENCES INC (NASDAQ), VACCINEX INC (NASDAQ), VERMILLION INC (NASDAQ), INFINITY PHARMACEUTICALS INC (NASDAQ), SYNLOGIC INC (NASDAQ), CATABASIS PHARMACEUTICALS INC (NASDAQ), COHBAR INC (NASDAQ), EQUILLIUM INC (NASDAQ), ENTASIS THERAPEUTICS HLDGS INC (NASDAQ), ORGANOVO HLDGS INC (NASDAQ), IMMUTEP LTD SPON ADS EACH REP 10 ORD SHS (NASDAQ), CATALYST BIOSCIENCES INC (NASDAQ), TREVENA INC (NASDAQ), PLURISTEM THERAPEUTICS INC (NASDAQ), CURIS INC (NASDAQ), NEWLINK GENETICS CORP (NASDAQ), GENOCEA BIOSCIENCES INC (NASDAQ), MERRIMACK PHARMACEUTICALS INC (NASDAQ), T2 BIOSYSTEMS INC (NASDAQ), OPIANT PHARMACEUTICALS INC (NASDAQ), SURFACE ONCOLOGY INC (NASDAQ), ALPINE IMMUNE SCIENCES INC (NASDAQ), APPLIED GENETIC TECHNOLOGIES CORP (NASDAQ), INMUNE BIO INC (NASDAQ), IDERA PHARMACEUTICALS INC (NASDAQ), KEZAR LIFE SCIENCES INC (NASDAQ), SAVARA INC (NASDAQ), AQUABOUNTY TECHNOLOGIES INC (NASDAQ), SUMMIT THERAPEUTICS PLC ADS EACH REPR 5 ORD (NASDAQ), ORGENESIS INC (NASDAQ), VASCULAR BIOGENICS LTD (NASDAQ), RESTORBIO INC (NASDAQ), SUNESIS PHARMACEUTICALS INC (NASDAQ), BELLICUM PHARMACEUTICALS (NASDAQ), MEREO BIOPHARMA GROUP PLC SPON ADS EACH REP 5 ORD SHS (NASDAQ), ITERUM THERAPEUTICS PLC (NASDAQ), FORWARD PHARMA AS SPON ADS EACH REP 2 ORD SHS (NASDAQ), CELLDEX THERAPEUTICS INC (NASDAQ), OUTLOOK THERAPEUTICS INC (NASDAQ), HTG MOLECULAR DIAGNOSTICS INC (NASDAQ), ALIMERA SCIENCES INC (NASDAQ), EVOGENE LTD (NASDAQ), DIAMEDICA THERAPEUTICS INC (NASDAQ), ONCOLYTICS BIOTECH INC (NASDAQ), SIERRA ONCOLOGY INC (NASDAQ), BIOCARDIA INC (NASDAQ), ZAFGEN INC (NASDAQ), KAZIA THERAPEUTICS LIMITED SPON ADR EACH REP 10 ORD SHS (NASDAQ), FIBROCELL SCIENCE INC (NASDAQ), APTEVO THERAPEUTICS INC (NASDAQ), NEON THERAPEUTICS INC (NASDAQ), CONTRAFECT CORP (NASDAQ), INNOVATE BIOPHARMACEUTICALS INC (NASDAQ), SEELOS THERAPEUTICS INC (NASDAQ), BIONANO GENOMICS INC (NASDAQ), BIO-PATH HOLDINGS INC (NASDAQ), SELLAS LIFE SCIENCES GROUP INC (NASDAQ), MIRAGEN THERAPEUTICS INC (NASDAQ), MICROBOT MEDICAL INC (NASDAQ), UNUM THERAPEUTICS INC (NASDAQ), SOLIGENIX INC (NASDAQ), AZURRX BIOPHARMA INC (NASDAQ), AEVI GENOMIC MEDIC (NASDAQ), LEAP THERAPEUTICS INC (NASDAQ), VISTAGEN THERAPEUTICS INC (NASDAQ), CELLECTAR BIOSCIENCES INC (NASDAQ), CO DIAGNOSTICS INC (NASDAQ), IMMURON LIMITED SPON ADR EACH REPR 40 ORD SHS (NASDAQ), ATYR PHARMA INC (NASDAQ), AETERNA ZENTARIS INC (NASDAQ), PULMATRIX INCORPORATED (NASDAQ), SENESTECH INC (NASDAQ), DARE BIOSCIENCE INC (NASDAQ), PRECIPIO INC (NASDAQ), OCUGEN INC (NASDAQ), VAXART INC (NASDAQ), HEAT BIOLOGICS INC (NASDAQ), TOCAGEN INC (NASDAQ), ADVAXIS INC (NASDAQ), MIDATECH PHARMA PLC SPON ADS EACH REP 20 ORD SHS(R/S) (NASDAQ), BIOCEPT INC (NASDAQ), SOPHIRIS BIO INC (NASDAQ), ALTERITY THERAPEUTICS LIMITED SPON ADS EA REPR 60 ORD SHS (NASDAQ), ANCHIANO THERAPEUTICS LTD SPON ADS EACH REP 5 ORD SHS (NASDAQ), CONATUS PHARMACEUTICALS INC (NASDAQ), TROVAGENE INC (NASDAQ), TRACON PHARMACEUTICALS INC (NASDAQ), CYCLACEL PHARMA IN (NASDAQ), TRILLIUM THERAPEUTICS INC (NASDAQ), GENETIC TECHNOLOGIES SPON ADS EA REP 600 ORD SHS(R/S) (NASDAQ), CLEVELAND BIOLABS INC (NASDAQ), BENITEC BIOPHARMA LTD SPON ADS EA REPR 200 ORD SHS(POST SPLIT) (NASDAQ), ARCA BIOPHARMA INC (NASDAQ), PLUS THERAPEUTICS INC (NASDAQ), ACHIEVE LIFE SCIENCE INC (NASDAQ), ENDRA LIFE SCIENCES INC (NASDAQ), XENETIC BIOSCIENCES INC (NASDAQ), REXAHN PHARMACEUTICALS INC (NASDAQ), CAPRICOR THERAPEUTICS INC (NASDAQ), OPGEN INC (NASDAQ), XTL BIOPHARMACEUTICALS LTD SPON ADS EACH REP 100 ORD SHS(POST SPLT) (NASDAQ), CELLECT BIOTECHNOLOGY LTD SPON ADS EACH REP 100 ORD SHS(POST SPLT) (NASDAQ), PROTEON THERAPEUTICS INC (NASDAQ), THERAPIX BIOSCIENCES LTD SPON ADR EACH REP 40 ORD (POST SPLIT) (NASDAQ), PHIO PHARMACEUTICALS CORP (NASDAQ), DIFFUSION PHARMACEUTICALS INC (NASDAQ), SENECA BIOPHARMA INC (NASDAQ), AURIS MEDICAL HOLDING LTD (NASDAQ), SPHERIX INC (NASDAQ), INVIVO THERAPEUTICS HOLDING CORP (NASDAQ), ONCONOVA THERAPEUTICS INC (NASDAQ)
Global Peer CSL ASX 126,043.682 46.980 46.980 16.8437 0.955
Global Peer AMGEN-T HKEx 594,184.000 9.032 9.399 6.9364 4.385
Global Peer AGILENT TECHNOLOGIES INC NYSE 25,230.926 79.844 23.558 5.3140 0.751
Global Peer SINO BIOPHARM HKEx 132,570.172 12.372 12.841 3.9481 0.694
Global Peer WUXI BIO HKEx 116,388.873 155.827 121.822 11.9807 -
Global Peer BEIGENE HKEx 90,826.622 - - 9.0622 -
Global Peer GENSCRIPT BIO HKEx 36,039.897 216.743 - 10.1634 -
Global Peer Lonza SGX 5,937.453 7.663 9.330 0.6935 4.766
Global Peer 3SBIO HKEx 28,244.466 18.671 22.726 2.7838 -
Global Peer EMERGENT BIOSOLUTIONS INC NYSE 2,714.390 43.292 631.253 2.6226 -
Other Global Peers HAOHAI BIOTEC (HKEx), MYOVANT SCIENCES LTD (NYSE), FRONTAGE (HKEx), CKLIFE SCIENCES (HKEx), VIVA BIOTECH (HKEx), AVITA MEDICAL LTD (ASX), ASCENTAGE-B (HKEx), POLYNOVO LIMITED (ASX), KADMON HLDGS INC (NYSE), MESOBLAST LTD (ASX), SINOMAB BIO-B (HKEx), ASCLETIS-B (HKEx), ESSEX BIO-TECH (HKEx), ARCUS BIOSCIENCES INC (NYSE), STARPHARMA HOLDINGS LIMITED (ASX), LEE'S PHARM (HKEx), TELIX PHARMACEUTIC (ASX), NEXT SCIENCE LTD (ASX), PFENEX INC (NYSE American), DPHARMA (Bursa), NEUREN PHARMACEUTICALS LTD (ASX), BBI LIFE SCI (HKEx), NANOVIRICIDES INC (NYSE American), NAVIDEA BIOPHARMACEUTICALS INC (NYSE American), RESAPP HEALTH LIMITED (ASX), ENZO BIOCHEM INC (NYSE), MATINAS BIOPHARMA HOLDINGS INC (NYSE American), UNI-BIO GROUP (HKEx), PALATIN TECHNOLOGIES INC (NYSE American), LINEAGE CELL THERAPEUTICS INC (NYSE American), PYC THERAPEUTICS LIMITED (ASX), 22ND CENTURY GROUP INC (NYSE American), IMUGENE LIMITED (ASX), ONCOSIL MEDICAL LIMITED (ASX), CYNATA THERAPEUTICS LTD (ASX), CEL-SCI CORP (NYSE American), IMMUTEP LTD (ASX), ORTHOCELL LIMITED (ASX), SYNTHETIC BIOLOGICS INC (NYSE American), CT ENTERPRISE (HKEx), ARMATA PHARMACEUTICALS INC (NYSE American), PORT (SET), BIONOMICS LTD (ASX), ISORAY INC (NYSE American), ACTINOGEN MEDICAL LTD (ASX), KAZIA THERAPEUTICS LIMITED (ASX), BIOSINO BIO-TEC (HKEx), INVEX THERAPEUTICS LTD NPV (ASX), ORAGENICS INC (NYSE American), MEMPHASYS LTD (ASX), REGENT PACIFIC (HKEx), PRESCIENT THERAPEUTICS LIMITED (ASX), IBIO INC (NYSE American), NOVITA HEALTHCARE LTD (ASX), BIOTRON (ASX), RHINOMED LIMITED (ASX), INDIA GLOBALIZATION CAPITAL INC (NYSE American), EXTRAWELL PHAR (HKEx), ACTINIUM PHARMACEUTICALS INC (NYSE American), PROTEOMICS INTL LABORATORIES LTD (ASX), ANTEOTECH LIMITED (ASX), REGENEUS LTD (ASX), CELLMID LIMITED (ASX), IMMURON LIMITED (ASX), PATRYS LIMITED (ASX), NEUROSCIENTIFIC BIOPHARMA LTD (ASX), CONTANGO ASSET MANAGEMENT LIMITED (ASX), CAN FITE BIOPHARMA LTD SPON ADS EA REP 30 ORD SHS(POST REV SPL (NYSE American), ALTERITY THERAPEUTICS LIMITED (ASX), Suntar Eco-City^ (SGX), ADALTA LTD (ASX), HOLISTA COLLTECH LIMITED (ASX), GENETIC TECHNOLOGIES (ASX), BENITEC BIOPHARMA LTD (ASX), NOVABAY PHARMACEUTICALS INC (NYSE American), AUSTRALIAN PRIMARY HEMP LTD (ASX), MEGASUN (Bursa), CCP TECHNOLOGIES LTD (ASX), MGRC (Bursa), HAO WEN HLDGS (HKEx), MEDIBIO LIMITED (ASX), LIVING CELL TECHNOLOGIES (ASX), ANATARA LIFESCIENCES LTD (ASX), TBG DIAGNOSTICS LTD (ASX), BIOXYNE LIMITED (ASX), QT Vascular (SGX), AVECHO BIOTECHNOLOGY LTD (ASX), AIM IMMUNOTECH INC (NYSE American), BPH ENERGY LIMITED (ASX), AMPLIA THERAPEUTICS LTD (ASX), NANOLLOSE LTD (ASX), FACTOR THERAPEUTICS LIMITED (ASX)
Notes:
  1. For companies, Market Cap is based on the trading currency of the company. Industry/Index Market Cap is the average market cap for that industry/index.
  2. Industry/Index PE is calculated using (Total Market Cap/Total Earnings) of all companies in the industry/index.
  3. Industry/Index Price/NAV is calculated using (Total Market Cap/Total Shareholders' Equity) of all companies in the industry/index.
  4. Industry/Index Dividend Yield is calculated using (Total Gross Dividend/Total Market Cap) of all companies in the industry/index.
  5. For Industry/Index calculation, data for foreign currency denominated companies will be converted to the main market currency using the latest exchange rate.
  6. Industry/Index/Peers data is updated daily.
  7. Peers are sorted by market capitalisation and only details for the top 10 will be shown.

Total Shareholder Return

PeriodDividend ReceivedCapital AppreciationTotal Shareholder Return
Short Term Return 5 Days -+0.027
+29.03 %
10 Days --0.026
-17.81 %
20 Days --0.030
-20.00 %
Medium Term Return 3 Months --0.472
-79.73 %
6 Months --0.930
-88.57 %
1 Year --6.830
-98.27 %
Long Term Return 2 Years --9.240
-98.72 %
3 Years --5.510
-97.87 %
Annualised Return Annualised --
-72.27 %
Notes:
  1. Total Shareholder Return (TSR) combines share price appreciation and dividends paid to show the total return to the shareholder expressed as a percentage.
  2. Script dividends are ignored in this calculation.

Price Movements

1 Year Range 0.075 - 11.500 Change From 1 Year Low +0.045 % Change From 1 Year Low (%) +60.00
Change From 1 Year High -11.380 % Change From 1 Year High (%) -98.96
2 Years Range 0.075 - 11.523 Change From 2 Years Low +0.045 % Change From 2 Years Low (%) +60.00
Change From 2 Years High -11.403 % Change From 2 Years High (%) -98.96
5 Years Range 0.075 - 13.750 Change From 5 Years Low +0.045 % Change From 5 Years Low (%) +60.00
Change From 5 Years High -13.630 % Change From 5 Years High (%) -99.13
Notes:
  1. Price movements are based on adjusted historical data.

Company Background

Motif Bio Plc is a clinical stage biopharmaceutical company, which engages in the development and commercialization of pharmaceutical formulations. The company focuses on developing novel antibiotics designed to be effective against serious and life-threatening infections caused by multi-drug resistant bacteria. It offers Iclaprim, a novel diaminopyrimidine antibiotic that inhibits an essential bacterial enzyme called dihydrofolate reductase. The company was founded by Jonathan E. Gold on November 20, 2014 and is headquartered in Princeton, NJ.

Historical Price Data

Date Open High Low Close Volume VWAP
05 Dec 2019 0.125 0.129 0.110 0.120 664,207 -
04 Dec 2019 0.147 0.148 0.120 0.130 1,602,336 -
03 Dec 2019 0.100 0.140 0.095 0.140 3,130,273 -
02 Dec 2019 0.100 0.102 0.090 0.093 586,388 -
29 Nov 2019 0.109 0.110 0.093 0.093 551,254 -
27 Nov 2019 0.086 0.110 0.080 0.100 2,683,604 -
26 Nov 2019 0.131 0.146 0.075 0.095 3,187,471 -
25 Nov 2019 0.153 0.157 0.145 0.151 219,074 -
22 Nov 2019 0.160 0.164 0.146 0.146 224,124 -
21 Nov 2019 0.180 0.180 0.150 0.154 132,696 -
20 Nov 2019 0.158 0.163 0.145 0.160 212,766 -
19 Nov 2019 0.146 0.155 0.145 0.151 237,132 -
18 Nov 2019 0.170 0.170 0.141 0.155 435,318 -
15 Nov 2019 0.170 0.170 0.151 0.159 452,986 -
14 Nov 2019 0.150 0.210 0.150 0.168 2,957,553 -
13 Nov 2019 0.148 0.148 0.143 0.146 136,105 -
12 Nov 2019 0.145 0.160 0.138 0.141 431,031 -
11 Nov 2019 0.158 0.165 0.136 0.138 219,076 -
08 Nov 2019 0.163 0.170 0.127 0.150 584,317 -
07 Nov 2019 0.170 0.174 0.161 0.163 393,338 -
06 Nov 2019 0.179 0.180 0.171 0.176 166,982 -
05 Nov 2019 0.200 0.200 0.173 0.180 498,303 -
Summary
Current 2 Weeks
(21 Nov 2019 to 05 Dec 2019)
0.180 0.180 0.075 0.120 12,981,427 -
Previous 2 Weeks
(07 Nov 2019 to 20 Nov 2019)
0.170 0.180 0.075 0.160 6,059,622 -
4 Weeks from
(10 Oct 2019 to 06 Nov 2019)
0.225 0.225 0.075 0.176 14,297,263 -
View All Historical Data

More Information Available

More information is available to our subscribers, including:

  • Market Moving News from Dow Jones Newswires
  • Consensus Estimates
  • Dividend/Distribution History
  • Financial Summary with Financial Period Comparison
  • Comprehensive Financial Ratios(ROA, ROE, Price/Revenue, Net Earnings Margin, Current Ratio, Debt to Equity Ratio etc)
  • Events Calendar for Results Announcements, Ex-Dates etc
  • Insider Buying and Selling Report

If you are an existing subscriber, please login. If not, read up on what you are missing out in our Help Centre and join us as a subscriber.

Disclaimer:

While reasonable efforts have been taken to ensure that the calculations performed by the features of this site are reliable, the features are provided on the basis that:-

  1. no liability is accepted for any errors or inaccuracies resulting from your use of these features;
  2. many of the data inputs (including share prices) are obtained from third party sources for which we assume no responsibility.